Literature DB >> 16970572

Gastrointestinal manifestations of chronic granulomatous disease.

A Huang1, F Abbasakoor, C J Vaizey.   

Abstract

OBJECTIVE: Chronic granulomatous disease is a rare clinical entity characterized by recurrent infective and inflammatory complications. Patients are usually assigned to specialist centres, but nonspecialist clinicians may be required to treat these patients in the emergency setting. This review serves as a management guide to those clinicians who are faced with patients presenting with gastrointestinal manifestations of chronic granulomatous disease.
METHODS: This review is based on a literature search (Medline and NLM PubMed) with manual cross-referencing of all articles related to gastrointestinal chronic granulomatous disease.
RESULTS: Gastrointestinal tract involvement is present in most affected patients. Clinical presentation can mimic common surgical complications such as colitis, perianal sepsis, gastric outlet obstruction and liver abscess. A history of recurrent infections during childhood is common. Management involves haematological, microbiological, endoscopic and radiological investigations. Treatment modalities include early aggressive empirical antimicrobial therapy for sepsis, immunomodulation for inflammatory complications and surgical drainage of abscesses.
CONCLUSION: Early involvement of a centre with immunological expertise combined with aggressive management of complications significantly improves morbidity and mortality from this rare condition.

Entities:  

Mesh:

Year:  2006        PMID: 16970572     DOI: 10.1111/j.1463-1318.2006.01030.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  20 in total

1.  Adaptive immune defects against glycoantigens in chronic granulomatous disease via dysregulated nitric oxide production.

Authors:  Colleen J Lewis; Brian A Cobb
Journal:  Eur J Immunol       Date:  2011-08-04       Impact factor: 5.532

Review 2.  ROS in gastrointestinal inflammation: Rescue Or Sabotage?

Authors:  G Aviello; U G Knaus
Journal:  Br J Pharmacol       Date:  2016-03-03       Impact factor: 8.739

3.  Gastrointestinal histopathology in chronic granulomatous disease: a study of 87 patients.

Authors:  Meghna Alimchandani; Jin-Ping Lai; Phyu Phyu Aung; Sajneet Khangura; Natasha Kamal; John I Gallin; Steven M Holland; Harry L Malech; Theo Heller; Markku Miettinen; Martha M Quezado
Journal:  Am J Surg Pathol       Date:  2013-09       Impact factor: 6.394

Review 4.  Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes.

Authors:  Shradha Agarwal; Lloyd Mayer
Journal:  J Allergy Clin Immunol       Date:  2009-08-08       Impact factor: 10.793

Review 5.  Chronic granulomatous disease.

Authors:  Alexander J Towbin; Ian Chaves
Journal:  Pediatr Radiol       Date:  2010-02-05

Review 6.  Gastrointestinal Manifestations and Complications of Primary Immunodeficiency Disorders.

Authors:  Shradha Agarwal; Charlotte Cunningham-Rundles
Journal:  Immunol Allergy Clin North Am       Date:  2019-02       Impact factor: 3.479

7.  Decreased STAT5 phosphorylation and GATA-3 expression in NOX2-deficient T cells: role in T helper development.

Authors:  Kristen E Shatynski; Haiyan Chen; Jaeyul Kwon; Mark S Williams
Journal:  Eur J Immunol       Date:  2012-10-01       Impact factor: 5.532

Review 8.  Spectrum of imaging findings of chronic granulomatous disease: a single center experience.

Authors:  Minah Lee; Mu Sook Lee; Jeong Sub Lee; Su Yeon Ko; Sun Young Jeong
Journal:  Diagn Interv Radiol       Date:  2017 Nov-Dec       Impact factor: 2.630

Review 9.  Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD).

Authors:  Mathieu Uzzan; Huaibin M Ko; Saurabh Mehandru; Charlotte Cunningham-Rundles
Journal:  Curr Gastroenterol Rep       Date:  2016-04

10.  Chronic granulomatous disease.

Authors:  Erik C von Rosenvinge; Thomas G O'Donnell; Steven M Holland; Theo Heller
Journal:  Inflamm Bowel Dis       Date:  2010-01       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.